Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

Article

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Patrick Y. Wen, MD

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme (GBM) merit further exploration in a phase III study, based on the substantial improvement in overall survival (OS) with the immunotherapy, according to lead investigator Patrick Y. Wen, MD, at the 2015 Society for Neuro-Oncology Annual Meeting.

In a group of patients with HLA-A2+ newly diagnosed GBM, which is the population selected for the phase III study, an immune response to ICT-107 by enzyme-linked immunospot (ELISPOT) corresponded to a prolongation in OS. These findings help predict potential results from the larger study for ICT-107, which is composed of autologous dendritic cells incubated with 6 synthetic peptide CTL epitopes that target the GBM/stem cell-associated antigens MAGE-1, HER2, AIM-2, TRP-2, gp100, and IL-13Rα2.

In the HLA-A2 group of responders from the phase II study, the median OS was 23.1 months compared with 13.7 months in non-responders (P = .0674). For responders, OS was extended by 52% compared with 29% in non-responders (P = .0615). Additionally, progression-free survival (PFS) was extended by 41% versus 15% in non-responders (P = .0259).

“ICT 107 is a dendritic cell peptide vaccine that has shown promising results in a randomized phase II study in patients with newly-diagnosed glioblastomas and was very well-tolerated,” Wen, director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, told OncLive. “If the recently launched phase III study confirms these findings, it will bring a much-needed treatment to our patients.”

In the phase II study, 124 patients were randomized in a 2:1 ratio to receive ICT-107 or matching control (unincubated dendritic cells). Seventy-seven patients were HLA-A2-positive. Patients in the treatment arm (n = 81) received four induction doses of ICT-107 after chemoradiation, and then maintenance doses until progression. All patients in the trial received temozolomide as standard-of-care. The primary endpoint of the trial was OS. Secondary endpoints included PFS along with other measures.

For the full population of the trial, the median OS with ICT-107 was 18.3 versus 16.7 months for control (HR, 0.89, P = .643). Median PFS was 11.2 months with ICT-107 compared with 9.0 months in the control arm (HR, 0.57, P = .011).

When censored to 7.5 months post-treatment in the HLA-A2-positive group, a response to ICT-107 as measured using immune criteria was found to significantly correlate with improvements in OS. At this time point, the median OS with ICT-107 was 17.6 versus 13.7 months (P = .0018). Sixty percent of ICT-107-treated patients demonstrated a statistically significant immune response compared with 36% of patients in the control arm (P = 0.0084).

Furthermore, levels of IL-12 production were linked with survival. In the censored group, high IL-12 producers had a median OS of 20.6 months compared with 15.4 months for low producers (P = .0515). In the full population of HLA-A2+ responders, those who produced high levels of IL-12 had an extension in OS of 54% versus 31% in IL-12 low producers (P = .0426). In the high group, PFS was extended by 43% versus 19% in the low group (P = .0293).

“The final data from the phase II trial continue to demonstrate the therapeutic value of ICT-107 as a potential treatment for patients with newly diagnosed glioblastoma, and strongly support advancing to phase III testing,” John S. Yu, MD, founder of ImmunoCellular Therapeutics, the manufacturer of ICT-107, said in a statement.

The phase III registration trial will enroll more than 400 HLA-A2+ patients with GBM in approximately 120 sites in the United States, Canada, and the European Union. Patients will be randomized to received temozolomide plus control or ICT-107. The primary endpoint of the trial will be OS and secondary endpoints will be PFS and safety, as well as OS in the two pre-specified MGMT subgroups. The phase III study will employ a different control comprised of the patients’ own monocytes, which are less immunologically active than dendritic cells.

The phase III trial was formed under a special protocol assessment with the FDA, which was granted in August 2015. The study hopes to begin enrolling patients soon. Special protocol assessment is a written agreement between the sponsor company, ImmunoCellular Therapeutics, and the FDA on the design, clinical endpoints, size, and statistical design of a clinical trial. The agreement is intended support findings submitted to the FDA for regulatory filings.

Wen P, Reardon D, Phuphanich S, et al. Association of survival and progression-free survival with immune response in HLA-A2+ newly-diagnosed GBM patients in randomized double-blind placebo-controlled phase 2 trial of dendritic cell (DC) immunotherapy with ICT-107. Presented at: 2015 Annual Meeting of the Society for Neuro-Oncology; November 19-22, 2015; San Antonio, TX. Abstract IMCT-20.

<<<

View more from the 2015 SNO Meeting

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center